Biotechnology & Drugs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology & Drugs

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: 2MAR$ who started this subject	2/28/2004 4:41:30 PM
From: 2MAR$	Read Replies (1) of 232

Jan 22 SEPR $28~$26 beats by $0.30, beats on revs (SEPR) 27.38: Reports Q4 (Dec) loss of $0.40 per share, $0.30 better than the Reuters Research consensus of ($0.70); revenues rose 42.3% year/year to $112.3 mln vs the $94.6 mln consensus. 19-Dec-03 13:23 ET In Play 200 Day Alert -- Sepracor (SEPR) 23.00 -0.63: -- Technical -- Edged to new session low in recent action and probed support at its 200 day exp mov avg of 22.80 (session low 22.86) before stabilizing. If follow through develops, next support is its Dec low and 200 day simple mov avg which come into play at 22.69/22.67. The four month low from Nov is at 21.96. 18-Dec-03 07:25 ET In Play Sepracor starts Phase IIIB studies (SEPR) 23.58: Co initiates Phase IIIB studies for Estorra brand eszopiclone. These studies are designed to evaluate eszopiclone in the treatment of insomnia in patients suffering from depression, in patients with rheumatoid arthritis and in women who experience symptoms of perimenopause.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next